{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:48:07Z","timestamp":1791953287410,"version":"4.3.4"},"reference-count":89,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>IgA nephropathy is the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and kidney failure in young and middle-aged adults, characterized by considerable ethnic differences in incidence and prognosis. This review summarises the evidence that these differences are, at least in part, genetically determined and maps the identified susceptibility loci onto the pathogenic sequence of the disease. Worldwide prevalence gradient increases with eastward and northward distance from Africa, while showing the significance of ancestry rather than environment in diaspora populations. Familial clustering provides support for an inherited component, while methylation differences between monozygotic twins discordant for IgAN point to an additional epigenetic layer. Genome-wide association studies (GWAS) in Han Chinese, European, and Korean cohorts have identified susceptibility loci implicated in antigen presentation, mucosal and intestinal IgA immunity, complement regulation, and innate immune signaling. Mapping these loci onto the four-hit hypothesis shows that inherited variation acts at distinct, potentially separable nodes. The MHC region contributes approximately half of the SNP-based heritability, while the CFH\/CFHR locus provides the strongest signal outside the MHC. The complement arm has become the principal therapeutic target because it is currently the most pharmacologically tractable. We conclude by reviewing mechanism-directed therapies together with the safety questions and patient-selection issues that accompany them.<\/jats:p>","DOI":"10.3390\/ijms27198821","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:14:56Z","timestamp":1790936096000},"page":"8821","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From Susceptibility Loci to Therapeutic Targets: The Genetic Architecture of IgA Nephropathy"],"prefix":"10.3390","volume":"27","author":[{"given":"Miko\u0142aj","family":"Dopiera\u0142a","sequence":"first","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Medicine, Poznan University of Medical Sciences, 61-701 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Nitz","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Medicine, Poznan University of Medical Sciences, 61-701 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Bursy","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Medicine, Poznan University of Medical Sciences, 61-701 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonina","family":"Garbowska","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Medicine, Poznan University of Medical Sciences, 61-701 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiktoria","family":"Dopiera\u0142a","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Medicine, Poznan University of Medical Sciences, 61-701 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Schwermer","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Medicine, Poznan University of Medical Sciences, 61-701 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6237-0814","authenticated-orcid":false,"given":"Krzysztof","family":"Pawlaczyk","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Medicine, Poznan University of Medical Sciences, 61-701 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","article-title":"Epidemiology of IgA Nephropathy: A Global Perspective","volume":"38","author":"Schena","year":"2018","journal-title":"Semin. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.34067\/KID.0000000000000165","article-title":"Global Incidence of IgA Nephropathy by Race and Ethnicity: A Systematic Review","volume":"4","author":"Kiryluk","year":"2023","journal-title":"Kidney360"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Kiryluk, K., Li, Y., Sanna-Cherchi, S., Rohanizadegan, M., Suzuki, H., Eitner, F., Snyder, H.J., Choi, M., Hou, P., and Scolari, F. (2012). Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis. PLoS Genet., 8.","DOI":"10.1371\/journal.pgen.1002765"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.kint.2025.04.003","article-title":"Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)","volume":"108","author":"Floege","year":"2025","journal-title":"Kidney Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.semnephrol.2007.10.006","article-title":"Racial and Genetic Factors in IgA Nephropathy","volume":"28","author":"Hsu","year":"2008","journal-title":"Semin. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Hall, Y.N., Fuentes, E.F., Chertow, G.M., and Olson, J.L. (2004). Race\/ethnicity and disease severity in IgA nephropathy. BMC Nephrol., 5.","DOI":"10.1186\/1471-2369-5-10"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/ki.2013.210","article-title":"Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease","volume":"84","author":"Barbour","year":"2013","journal-title":"Kidney Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000381738","article-title":"The Genetics of IgA Nephropathy: An Overview from Western Countries","volume":"1","author":"Feehally","year":"2015","journal-title":"Kidney Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s00467-010-1500-7","article-title":"Genetic studies of IgA nephropathy: Past, present, and future","volume":"25","author":"Kiryluk","year":"2010","journal-title":"Pediatr. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Xu, L.L., Zhou, X.J., and Zhang, H. (2023). An Update on the Genetics of IgA Nephropathy. J. Clin. Med., 13.","DOI":"10.3390\/jcm13010123"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/ki.2015.252","article-title":"New developments in the genetics, pathogenesis, and therapy of IgA nephropathy","volume":"88","author":"Magistroni","year":"2015","journal-title":"Kidney Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000503564","article-title":"An Exome Sequencing Study of 10 Families with IgA Nephropathy","volume":"144","author":"Stapleton","year":"2020","journal-title":"Nephron"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1681\/ASN.2007020241","article-title":"Genome-Wide Linkage Scan of a Large Family with IgA Nephropathy Localizes a Novel Susceptibility Locus to Chromosome 2q36","volume":"18","author":"Paterson","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMra020109","article-title":"IgA Nephropathy","volume":"347","author":"Donadio","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ekir.2020.10.015","article-title":"Increased Lifetime Risk of ESRD in Familial IgA Nephropathy","volume":"6","author":"Shi","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/81677","article-title":"IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22\u201323","volume":"26","author":"Gharavi","year":"2000","journal-title":"Nat. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1556-0864(15)31506-9","article-title":"The Ras\/Raf\/MAPK Pathway","volume":"1","author":"Molina","year":"2006","journal-title":"J. Thorac. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1038\/ejhg.2015.52","article-title":"A SPRY2 mutation leading to MAPK\/ERK pathway inhibition is associated with an autosomal dominant form of IgA nephropathy","volume":"23","author":"Milillo","year":"2015","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ekir.2020.04.011","article-title":"Type IV Collagen Mutations in Familial IgA Nephropathy","volume":"5","author":"Li","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1681\/ASN.2016020184","article-title":"IgA1 Glycosylation Is Heritable in Healthy Twins","volume":"28","author":"Visconti","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000512169","article-title":"Monozygotic Twins Discordant for Immunoglobulin A Nephropathy Display Differences in DNA Methylation and Gene Expression","volume":"7","author":"Wei","year":"2021","journal-title":"Kidney Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/ng.1047","article-title":"A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy","volume":"44","author":"Yu","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2215\/CJN.06910520","article-title":"Exome Chip Analyses and Genetic Risk for IgA Nephropathy among Han Chinese","volume":"16","author":"Zhou","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000520039","article-title":"IgA Nephropathy: A Chinese Perspective","volume":"2","author":"Zhang","year":"2021","journal-title":"Glomerular Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1681\/ASN.0000000000000222","article-title":"Genome-Wide Association Analysis of Protein-Coding Variants in IgA Nephropathy","volume":"34","author":"Li","year":"2023","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ng.787","article-title":"Genome-wide association study identifies susceptibility loci for IgA nephropathy","volume":"43","author":"Gharavi","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1681\/ASN.2015111210","article-title":"Fine Mapping Implicates a Deletion of CFHR1 and CFHR3 in Protection from IgA Nephropathy in Han Chinese","volume":"27","author":"Xie","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"83031","DOI":"10.18632\/oncotarget.12965","article-title":"TLR1 polymorphism rs4833095 as a risk factor for IgA nephropathy in a Chinese Han population: A case-control study","volume":"7","author":"Gao","year":"2016","journal-title":"Oncotarget"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1744-313X.2010.00978.x","article-title":"Toll-like receptor 1 gene polymorphisms in childhood IgA nephropathy: A case-control study in the Korean population: Toll-like receptor 1 gene polymorphisms in childhood IgA nephropathy","volume":"38","author":"Lee","year":"2011","journal-title":"Int. J. Immunogenet."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ding, X., Mei, Y., Mao, Z., Long, L., Han, Q., You, Y., and Zhu, H. (2021). Association of Immune and Inflammatory Gene Polymorphism With the Risk of IgA Nephropathy: A Systematic Review and Meta-Analysis of 45 Studies. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.683913"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/humu.20543","article-title":"Variants of the ST6GALNAC2 promoter influence transcriptional activity and contribute to genetic susceptibility to IgA nephropathy","volume":"28","author":"Li","year":"2007","journal-title":"Hum. Mutat."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Pan, M., Zhang, J., Li, Z., Jin, L., Zheng, Y., Zhou, Z., Zhen, S., and Lu, G. (2017). Increased C4 and decreased C3 levels are associated with a poor prognosis in patients with immunoglobulin A nephropathy: A retrospective study. BMC Nephrol., 18.","DOI":"10.1186\/s12882-017-0658-7"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s10038-019-0699-9","article-title":"Identification of susceptibility locus shared by IgA nephropathy and inflammatory bowel disease in a Chinese Han population","volume":"65","author":"Shi","year":"2020","journal-title":"J. Hum. Genet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e2966","DOI":"10.1002\/jgm.2966","article-title":"Association of TNFSF13 polymorphisms with IgA nephropathy in a Chinese Han population","volume":"19","author":"Zhong","year":"2017","journal-title":"J. Gene Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1681\/ASN.2021111447","article-title":"Genetic Variants of the COL4A3, COL4A4, and COL4A5 Genes Contribute to Thinned Glomerular Basement Membrane Lesions in Sporadic IgA Nephropathy Patients","volume":"34","author":"Yuan","year":"2023","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3118","article-title":"Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens","volume":"46","author":"Kiryluk","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Chronopoulou, I., Tziastoudi, M., Pissas, G., Dardiotis, E., Dardioti, M., Golfinopoulos, S., Filippidis, G., Mertens, P.R., Tsironi, E.E., and Liakopoulos, V. (2023). Interleukin Variants Are Associated with the Development and Progression of IgA Nephropathy: A Candidate-Gene Association Study and Meta-Analysis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216347"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00467-009-1146-5","article-title":"Interleukin-1 cluster gene polymorphisms in childhood IgA nephropathy","volume":"24","author":"Hahn","year":"2009","journal-title":"Pediatr. Nephrol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3109\/0886022X.2011.568135","article-title":"Impact of Aldosterone Synthase Gene C-344T Polymorphism on IgA Nephropathy","volume":"33","author":"Bantis","year":"2011","journal-title":"Ren. Fail."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Jeong, K.H., Kim, J.S., Lee, Y.H., Kim, Y.G., Moon, J.-Y., Kang, S.W., Kim, T.H., Lee, S.H., Kim, Y.H., and KNOW-CKD Study Group (2019). Genome-wide association study identifies new susceptible loci of IgA nephropathy in Koreans. BMC Med. Genom., 12.","DOI":"10.1186\/s12920-019-0568-6"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41586-018-0137-8","article-title":"ANKRD16 prevents neuron loss caused by an editing-defective tRNA synthetase","volume":"557","author":"Vo","year":"2018","journal-title":"Nature"},{"key":"ref_42","first-page":"JCI33189","article-title":"IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1","volume":"11","author":"Suzuki","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1074\/jbc.M113.512277","article-title":"Cytokines Alter IgA1 O-Glycosylation by Dysregulating C1GalT1 and ST6GalNAc-II Enzymes","volume":"289","author":"Suzuki","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1681\/ASN.2011060567","article-title":"Abnormal miR-148b Expression Promotes Aberrant Glycosylation of IgA1 in IgA Nephropathy","volume":"23","author":"Serino","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Kiryluk, K., Li, Y., Moldoveanu, Z., Suzuki, H., Reily, C., Hou, P., Xie, J., Mladkova, N., Prakash, S., and Fischman, C. (2017). GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway. PLoS Genet., 13.","DOI":"10.1371\/journal.pgen.1006609"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1681\/ASN.2016091043","article-title":"Galactosylation of IgA1 Is Associated with Common Variation in C1GALT1","volume":"28","author":"Gale","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/ndt\/gfv032","article-title":"Role of let-7b in the regulation of N-acetylgalactosaminyltransferase 2 in IgA nephropathy","volume":"30","author":"Serino","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Placzek, W.J., Yanagawa, H., Makita, Y., Renfrow, M.B., Julian, B.A., Rizk, D.V., Suzuki, Y., Novak, J., and Suzuki, H. (2018). Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0190967"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/s41588-023-01422-x","article-title":"Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy","volume":"55","author":"Kiryluk","year":"2023","journal-title":"Nat. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1056\/NEJMoa1610528","article-title":"Overexpression of the Cytokine BAFF and Autoimmunity Risk","volume":"376","author":"Steri","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1681\/ASN.2014101044","article-title":"Somatic Mutations Modulate Autoantibodies against Galactose-Deficient IgA1 in IgA Nephropathy","volume":"27","author":"Huang","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1172\/JCI5535","article-title":"Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies","volume":"104","author":"Tomana","year":"1999","journal-title":"J. Clin. Investig."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Suzuki, H., and Novak, J. (2024). IgA Nephropathy: Significance of IgA1-Containing Immune Complexes in Clinical Settings. J. Clin. Med., 13.","DOI":"10.3390\/jcm13154495"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Knoppova, B., Reily, C., Maillard, N., Rizk, D.V., Moldoveanu, Z., Mestecky, J., Raska, M., Renfrow, M.B., Julian, B.A., and Novak, J. (2016). The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy. Front. Immunol., 7.","DOI":"10.3389\/fimmu.2016.00117"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.kint.2023.04.029","article-title":"IgA nephropathy: The lectin pathway and implications for targeted therapy","volume":"104","author":"Barratt","year":"2023","journal-title":"Kidney Int."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/nep.14350","article-title":"Pathogenesis of IgA nephropathy: Omics data inform glycomedicine","volume":"29","author":"Novak","year":"2024","journal-title":"Nephrology"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Zhang, H., Deng, Z., and Wang, Y. (2023). Molecular insight in intrarenal inflammation affecting four main types of cells in nephrons in IgA nephropathy. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1128393"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1681\/ASN.2014101000","article-title":"Current Understanding of the Role of Complement in IgA Nephropathy","volume":"26","author":"Maillard","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1681\/ASN.2014010096","article-title":"Variants in Complement Factor H and Complement Factor H-Related Protein Genes, CFHR3 and CFHR1, Affect Complement Activation in IgA Nephropathy","volume":"26","author":"Zhu","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_60","unstructured":"The EMPA-KIDNEY Collaborative Group (2024). Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: Secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol., 12, 51\u201360."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e2254054","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: A randomized clinical trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"ref_63","unstructured":"US Food and Drug Administration (2026, September 19). TARPEYO (Budesonide) Delayed-Release Capsules, for Oral Use: Prescribing Information. Revised December 2023, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215935s003lbl.pdf."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: A prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"ref_66","unstructured":"US Food and Drug Administration (2026, September 19). FILSPARI (Sparsentan) Prescribing Information. Revised August 2025, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/216403s005lbl.pdf."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2409415","article-title":"Atrasentan in patients with IgA nephropathy","volume":"392","author":"Heerspink","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_68","unstructured":"US Food and Drug Administration (2026, September 18). VANRAFIA (Atrasentan) Tablets, for Oral Use: Prescribing Information. Revised April 2025, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219208s000lbl.pdf."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.ekir.2023.01.041","article-title":"Targeting the alternative complement pathway with iptacopan to treat IgA nephropathy: Design and rationale of the APPLAUSE-IgAN study","volume":"8","author":"Rizk","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_70","unstructured":"US Food and Drug Administration (2026, September 18). FABHALTA (Iptacopan) Prescribing Information. Revised July 2026, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/218276s007lbl.pdf."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"ii9","DOI":"10.1093\/ckj\/sfad200","article-title":"The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy","volume":"16","author":"Yeo","year":"2023","journal-title":"Clin. Kidney J."},{"key":"ref_72","unstructured":"US Food and Drug Administration (2026, September 19). VOYXACT (Sibeprenlimab-Szsi) Injection, for Subcutaneous use: Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761434s000lbl.pdf."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2512133","article-title":"VISIONARY Trial Investigators Group. Sibeprenlimab in IgA nephropathy\u2014Interim analysis of a phase 3 trial","volume":"394","author":"Perkovic","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_74","unstructured":"US Food and Drug Administration (2026, September 19). TRUTAKNA (Atacicept-Vymj) Injection, for Subcutaneous Use: Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/761486Orig1s000lbl.pdf."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMoa2510198","article-title":"ORIGIN Phase 3 Trial Investigators. A phase 3 trial of atacicept in patients with IgA nephropathy","volume":"394","author":"Lafayette","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: The TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Barratt, J., Lafayette, R.A., and Floege, J. (2024). Therapy of IgA nephropathy: Time for a paradigm change. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1461879"},{"key":"ref_78","unstructured":"PureSpring Therapeutics\/ClinicalTrials.gov (2026, September 19). Phase I\/II Study of PS-002 in Adults with Primary IgA Nephropathy; FDA IND Clearance Announcement. NCT07182227, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07182227."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.kint.2025.11.017","article-title":"A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy","volume":"109","author":"Barbour","year":"2026","journal-title":"Kidney Int."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2215\/CJN.0000000000000384","article-title":"Phase 2 trial of cemdisiran in adult patients with IgA nephropathy: A randomized controlled trial","volume":"19","author":"Barratt","year":"2024","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_81","unstructured":"Arrowhead Pharmaceuticals (2026, September 19). Topline Phase 1\/2a Results for ARO-C3 in IgA Nephropathy (Sponsor-Reported). NCT05083364, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05083364."},{"key":"ref_82","unstructured":"ClinicalTrials.gov (2026, September 19). IMAgINATION: A Study to Evaluate the Efficacy and Safety of Sefaxersen in Participants with Primary IgA Nephropathy at High Risk of Progression. NCT05797610, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05797610."},{"key":"ref_83","unstructured":"AstraZeneca\/Alexion (2026, September 19). Prespecified Interim Analysis of the Phase III I CAN Trial of Ravulizumab in IgA Nephropathy (Sponsor-Reported). NCT04564339, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04564339."},{"key":"ref_84","unstructured":"PureSpring Therapeutics (2026, September 19). Preclinical PS-002 Data Presented at ASN Kidney Week 2024 (Conference\/Company Evidence). Available online: https:\/\/www.purespringtx.com\/."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1089\/hum.2024.156","article-title":"Thrombotic Microangiopathy Associated with Systemic Adeno-Associated Virus Gene Transfer: Review of Reported Cases","volume":"36","author":"Laforet","year":"2025","journal-title":"Hum. Gene Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1177\/10430342251378524","article-title":"Pre-Existing Anti-Adeno-Associated Virus Immunity in Gene Therapy: Mechanisms, Challenges, and Potential Solutions","volume":"36","author":"Iroanya","year":"2025","journal-title":"Hum. Gene Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"10728","DOI":"10.1038\/s41467-024-54475-9","article-title":"Enhancing gene transfer to renal tubules and podocytes by context-dependent selection of AAV capsids","volume":"15","author":"Furusho","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"101353","DOI":"10.1016\/j.blre.2025.101353","article-title":"Long-term durability of rAAV gene therapy in hemophilia: Factor expression, clinical outcomes and underlying molecular mechanisms","volume":"75","author":"Dargaud","year":"2026","journal-title":"Blood Rev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1681\/ASN.2020030349","article-title":"International IgA Nephropathy Network. Quantifying duration of proteinuria remission and association with clinical outcome in IgA nephropathy","volume":"32","author":"Canney","year":"2021","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/19\/8821\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:14:49Z","timestamp":1791951289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/19\/8821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":89,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["ijms27198821"],"URL":"https:\/\/doi.org\/10.3390\/ijms27198821","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]}}}